Scott Whitcup

Scott Whitcup is currently a Venture Partner at Vivo Capital, where he focuses on sourcing and managing early-stage investments across the biotechnology and healthcare sectors. Since joining the investment firm in 2022, he has supported a broader portfolio of over 50 active companies, specializing in the advancement of novel therapeutics, diagnostics, and medical devices. Prior to his current position, Whitcup held prominent investment roles at venBio Partners and Versant Ventures, building decades of extensive expertise in life sciences venture capital. Throughout his career, he has consistently guided funding strategies and provided operational guidance for emerging startups developing complex treatments in oncology, immunology, and rare diseases. His professional background centers on bridging clinical innovation with strategic venture funding to successfully scale early-stage medical device technology and biopharmaceutical enterprises across the broader global healthcare market.